NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
Clinical Trials
12 trialsNCT06427447 2025-02-04
ADJUPANC
Changhai Hospital
Phase 3 Recruiting
NCT06208436 2024-01-17
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Unknown
NCT00089024 2023-09-29
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Completed
NCT05679583 2023-01-11
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
Yonsei University
Phase 2 Recruiting
NCT00010166 2021-09-09
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
Wake Forest University Health Sciences
Phase 2 Completed
NCT01314027 2019-07-25
Adjuvant Versus Neoadjuvant Plus Adjuvant Chemotherapy in Resectable Pancreatic Cancer
University of Zurich
Phase 3 Terminated
NCT00536874 2017-03-16
Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01521702 2015-03-20
NEOPAC
Institut Paoli-Calmettes
Phase 3 Completed
NCT00524069 2013-02-01
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Roswell Park Cancer Institute
Phase NA Withdrawn
NCT00425841 2012-12-12
Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer
Technical University of Munich
Phase 2 Completed
NCT00410774 2012-09-17
Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery
University of California, San Francisco
Phase 1/2 Terminated